Drugs / Autologous CD34+ stem cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00788827 | Nov 2008 → May 2013 | type 1 diabetes mellitus, type 2 diabetes mellitus | Imperial College London | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous CD34+ stem cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00788827 ↗ |
| Known as | InsulinCytes | “In order to evaluate potential clinical applications for these recent advances we have designed a prospective Phase I clinical study of the expanded progeny of an adult CD34...” NCT00788827 ↗ |
| Modality | Cell therapy | “adult stem cell therapy” NCT00788827 ↗ |
| Route | Other | “injected directly into the body and tail of the pancreas” NCT00788827 ↗ |